Published in Blood Weekly, February 3rd, 2000
The efficient transduction of human hematopoietic stem cells (HSC) to the extent that they fully retain their engraftment potential and maintain high levels of transgene expression has not been reached, using current murine-based (MLV) retroviral vectors.
Integration of MLV-based vectors requires cells division by using different combination of cytokines in vitro that may effect the engraftment potential of HSC. Lentiviral vector-based gene delivery does not require cell proliferation; therefore, it may offer a more...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.